Latest factsheet
A high-level, monthly summary of key information about The Biotech Growth Trust.
Highlights from the commentary section include:
In August, the NAV per share was +7.9%, the share price was +8.5% and the benchmark NASDAQ Biotechnology Index (net, total return, sterling adjusted) was +9.8%;
Shares of Vogenx outperformed following a successful Phase 3 data readout from competitor Amylyx Pharmaceuticals. The positive trial results validated the therapeutic category for post-bariatric hypoglycemia and de-risked Vogenx's competing oral pipeline just days after its IPO;
Arcutis retraced recent gains despite strong second quarter results due to investor concerns around revenue growth in 2H26.
Factsheet archive
| Title | Document |
|---|---|
|
August 2026 Factsheet |
Download document: August 2026 Factsheet |
|
July 2026 Factsheet |
Download document: July 2026 Factsheet |
|
June 2026 Factsheet |
Download document: June 2026 Factsheet |
|
May 2026 Factsheet |
Download document: May 2026 Factsheet |
|
April 2026 Factsheet |
Download document: April 2026 Factsheet |
|
March 2026 Factsheet |
Download document: March 2026 Factsheet |
|
February 2026 Factsheet |
Download document: February 2026 Factsheet |
|
January 2026 Factsheet |
Download document: January 2026 Factsheet |
| Title | Document |
|---|---|
|
August 2026 Factsheet |
Download document: August 2026 Factsheet |
|
July 2026 Factsheet |
Download document: July 2026 Factsheet |
|
June 2026 Factsheet |
Download document: June 2026 Factsheet |
|
May 2026 Factsheet |
Download document: May 2026 Factsheet |
|
April 2026 Factsheet |
Download document: April 2026 Factsheet |
|
March 2026 Factsheet |
Download document: March 2026 Factsheet |
|
February 2026 Factsheet |
Download document: February 2026 Factsheet |
|
January 2026 Factsheet |
Download document: January 2026 Factsheet |